sanofi-aventis (formerly Aventis Pharma AG) is developing ilepatril (AVE-7688), a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, for the potential treatment of hypertension and diabetic nephropathy. Ilepatril is currently in phase IIb/... ...

请注册登录后继续浏览